Aurobindo Pharma: Acrotech Launches Adquey Ointment in US

Key Update: Aurobindo Pharma’s subsidiary Acrotech Biopharma has launched Adquey Ointment in the US. The launch marks the company’s entry into the dermatology market. Acrotech has established a dedicated dermatology business unit to support the new product and future opportunities in the segment. The move expands the company’s specialty-product portfolio in the US market. Fundamental Ratios: Key metrics such as P/E, ROE, ROCE and debt-to-equity should be reviewed along with the latest financial results. Risk Factors: USFDA and regulatory risks Pricing pressure and competition in the US pharmaceutical market Product launch and commercialization risks Patent and intellectual-property challenges Currency fluctuations and R&D costs Disclaimer: This content is for educational and informational purposes only and should not be considered investment advice. Investors should conduct their own research and consult a SEBI-registered investment professional before making investment decisions.